TransMedics Group, Inc. (TMDX) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2026. TransMedics Group, Inc. is a medical technology company developing the Organ Care System (OCS), a platform for organ preservation and transplantation, and the National OCS Program (NOP), which provides outsourced organ procurement and logistics services. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $189.9 million | $363.9 million |
| Net Income | $14.7 million | $22.0 million |
| Diluted EPS | $0.41 | $0.61 |
| Gross Margin | 60% | 59% |
| Operating Cash Flow | N/A | $41.8 million |
| Cash and Restricted Cash | $491.1 million (as of June 30, 2026) | $491.1 million |
| Total Debt (Principal) | $520.0 million ($460M Notes + $60M CIBC) | $520.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 21% year-over-year for the quarter ($32.6M increase) and 21% for the six-month period ($63.0M increase). Growth was driven primarily by higher sales volumes of OCS Liver disposable sets and increased usage of the NOP in the United States.
- Profitability Decline: Despite revenue growth, Net Income decreased significantly. For the quarter, net income fell from $34.9M to $14.7M (a 58% decrease). For the six months, it fell from $60.6M to $22.0M (a 64% decrease).
- Expense Increases: Operating expenses rose sharply. Research, development, and clinical trials expenses doubled to $31.6M for the quarter (up $15.7M), driven by external consulting for next-generation OCS and OCS Kidney development. Selling, general, and administrative (SG&A) expenses increased by $13.7M to $57.8M, largely due to personnel expansion and transaction-related costs.
- Interest Expense: Interest expense more than doubled to $7.2M for the quarter, primarily due to $3.8M in imputed interest on a new finance lease for the company's headquarters.
- Gross Margin Compression: Overall gross margin decreased from 61% to 60% (quarterly) and 61% to 59% (six-month). This was attributed to a higher mix of lower-margin service revenue and temporary increases in freight and inventory costs.
Guidance, Outlook, Risks, and Unusual Items
- New Headquarters Lease: In January 2026, the company entered into a finance lease for a new headquarters in Somerville, Massachusetts. This resulted in a significant increase in depreciation and imputed interest expenses. The company has a purchase option for the property.
- Internal Control Material Weakness: Management concluded that disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting. Specifically, controls over inventory movement within the manufacturing network were insufficient for interim reporting. A remediation plan has been implemented.
- Legal Proceedings: A consolidated class action lawsuit regarding alleged misstatements in 2022-2025 filings is proceeding to discovery. The court granted in part and denied in part the motion to dismiss in July 2026. The company cannot estimate potential losses.
- Outlook: Management expects operating and capital expenditures to continue increasing to support commercial growth, R&D for next-generation products (including OCS Kidney), and the relocation to the new headquarters. The company believes existing cash is sufficient for at least 12 months.
- Tax Rate: The effective tax rate for the six months ended June 30, 2026, was 21.1%, with a forecasted full-year 2026 rate between 25% and 27%.
Key Facts for Investor Verification
- Inventory Controls: Verify the progress of the remediation plan for the material weakness regarding inventory movement controls and assess the risk of future restatements or interim reporting errors.
- Expense Trajectory: Monitor the sustainability of the sharp increase in R&D and SG&A expenses, particularly the $10.6M increase in consulting fees and the impact of the new headquarters lease on future profitability.
- Revenue Mix: Track the ratio of product revenue to service revenue, as the shift toward lower-margin service revenue is compressing overall gross margins.
- Legal Exposure: Follow the status of the consolidated class action lawsuit (Jewik/Collins) as it moves through discovery to assess potential financial impact.
- Debt Covenants: Confirm continued compliance with the CIBC Credit Agreement covenants, specifically the minimum liquidity and revenue requirements, given the increased debt service costs.